PRCT Company Profile and Key Details

PROCEPT BioRobotics Corporation has 55.64 million shares outstanding. The public float is 53.56 million shares, elevated short interest at 17.19% of float. This equals 8.07 million shares. The short ratio is 5.15 days. Institutional investors hold 105.72% of the float. Insiders own 3.17%. CPMG Inc holds 11.22 million shares, MOLL FREDERIC H has 863.16 thousand shares and VIKING GLOBAL INVESTORS LP has 400.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 18.10 thousand shares across 9 transactions.

Short-term trend indicators are bullishly aligned (SMA20 -15.75%, SMA50 -22.49%, SMA200 -42.21%). The stock’s 14-day RSI is 28.36 (weak momentum), while the ATR of 2.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -66.62% below its high and over -9.91% above its low. Average 10-day trading volume of 1.70 million shares is in line with the 3-month average of 1.64 million, indicating normal recent market interest.

PROCEPT BioRobotics Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $76.41. This means the shares are trading below this model’s fair value.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) closed at $18.52 USD, losing -$0.70 (-3.64%) from the previous close of $19.22. The stock is currently within 5% of its 52-week low $17.96 and $60.57. With a market capitalization of about $1.05 billion, PROCEPT BioRobotics Corporation is classified as a small-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 1.63 million shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, PROCEPT BioRobotics Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Larry L. Wood, the company employs approximately 888 people and listed since September 15, 2021. PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology.

PROCEPT BioRobotics Corporation generated EPS of -$1.54 over the past year. Five-year average earnings growth is -12.56%. Wall Street analysts project EPS growth of 24.96% annually over the next five years. The latest quarter delivered EPS of -$0.56. The next quarter is forecast at -$0.44. Next year's EPS is expected at $13.49. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 6 Buy ratings, 4 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $62.00 to $25.00. The high target offers 222.58% upside. The low target suggests 30.07% downside. The mean target is $47.14. This offers 145.27% upside. PROCEPT BioRobotics Corporation earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by 1.82%. The prior quarter beat by 65.62%. Over the last six quarters, Apple has recorded several small beats. These include 2.94% in February 25, 2025.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares are flat -3.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows PROCEPT BioRobotics Corporation trading at a premium to the broader market with a P/E of -10.19. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $58.47, suggesting 204.21% upside. Our AI forecast model points to short-term weakness (-13.01% over two weeks), a medium-term fall (-72.53% over three months), and a longer-term loss (-30.65% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PROCEPT BioRobotics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.01%, with price expected at $16.72 by July 31, 2026, within a range of $14.85 to $18.80 3-Month Outlook: Projected fall of -72.53%, reaching $5.28 by October 12, 2026, with a range of $4.41 to $6.12. 1-Year Outlook: Projected loss of -30.65%, with price at $13.33 by July 20, 2027, within a range of $6.10 to $20.81.

PROCEPT BioRobotics Corporation trades at a P/E ratio of -10.19, slightly below the S&P 500 average, with a price-to-sales ratio of 3.28 and a price-to-book ratio of 3.01 trading at moderately above to book value. The P/FCF stands at -13.1, also above market averages.